A Study of PTX-9908 Injection for Non-resectable HCC with TACE — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of PTX-9908 Injection for Non-resectable HCC with TACE — Stella

Home/Carcinoma, Hepatocellular/

View on ClinicalTrials.gov

Recruiting

Back to Carcinoma, Hepatocellular trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Taiwan

National Taiwan University Hospital, New Taipei City, Taiwan

Key details

Phase

Early testing / Safety & dosing

Sponsor

TCM Biotech International Corp.

Enrollment target

~50 participants

Started

October 2020

Primary completion

August 2026

Age range

20 Years and older

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.